within Pharmacolibrary.Drugs.ATC.S;

model S01XA11
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 2.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0043,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01XA11</td></tr><td>route:</td><td>intramuscular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Nandrolone is a synthetic anabolic-androgenic steroid that is used medically for the treatment of anemia, osteoporosis, and other conditions requiring protein building and bone strengthening. Its use in sports is prohibited due to its performance-enhancing effects. The ATC code S01XA11 corresponds to ophthalmological use, but there is no evidence of nandrolone being used for this indication in approved clinical practice today.</p><h4>Pharmacokinetics</h4><p>Estimated typical pharmacokinetics for healthy adult males; no published PK studies for ophthalmic (S01XA11) route found, hence estimates based on systemic (intramuscular) nandrolone pharmacokinetics.</p><h4>References</h4><ol><li><p>Wijnand, HP, et al., &amp; Donker, CW (1985). Pharmacokinetic parameters of nandrolone (19-nortestosterone) after intramuscular administration of nandrolone decanoate (Deca-Durabolin) to healthy volunteers. <i>Acta endocrinologica. Supplementum</i> 271 19–30. DOI:<a href=&quot;https://doi.org/10.1530/acta.0.109s00019&quot;>10.1530/acta.0.109s00019</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3865478/&quot;>https://pubmed.ncbi.nlm.nih.gov/3865478</a></p></li><li><p>Bagchus, WM, et al., &amp; Geurts, TB (2005). Pharmacokinetic evaluation of three different intramuscular doses of nandrolone decanoate: analysis of serum and urine samples in healthy men. <i>The Journal of clinical endocrinology and metabolism</i> 90(5) 2624–2630. DOI:<a href=&quot;https://doi.org/10.1210/jc.2004-1526&quot;>10.1210/jc.2004-1526</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15713722/&quot;>https://pubmed.ncbi.nlm.nih.gov/15713722</a></p></li><li><p>van der Vies, J (1993). Pharmacokinetics of anabolic steroids. <i>Wiener medizinische Wochenschrift (1946)</i> 143(14-15) 366–368. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8256448/&quot;>https://pubmed.ncbi.nlm.nih.gov/8256448</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01XA11;
